Kornimate/medical-research-clean huggingface dataset:
a non-interventional study to identify children and adolescents with adhd and with or without mglur mutations

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this is a non-interventional study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (adhd) to assess cnvs in specific genes involved in glutamatergic signaling and neuronal connectivity. the screening in this study will be conducted through a combination of online and site performed activities.


Eligibility criteria:
inclusion criteria: 1. parent/legally authorized representative (lar) can speak and read english fluently, have provided informed consent and agree to be contacted for an interventional study prior to being genotyped. 2. subject is 6 to 17 years of age (inclusive) at the time of informed consent. 3. parent/lar confirms that the subject has been diagnosed with or been told by a doctor that their child has adhd. 4. parent/lar confirms that the subject is not pregnant and/or breastfeeding. exclusion criteria: 1. parent/lar confirms that the subject has been diagnosed with any of the following conditions (aside from adhd): conduct disorder, anxiety disorder, major depression, autism spectrum disorder (asd), bipolar disease, psychosis, hypertension, seizure disorder, syncope, or other serious cardiac problems. 2. aside from your child's current adhd medication (if applicable), parent/lar confirms that the subject is currently taking any of the following medications: antidepressants, anti-anxiety medications, anti-psychotics, and/or mood stabilizers. 3. parent/lar confirms that the subject has been genotyped previously in the mdgn-nfc1-adhd-001, mdgn-nfc1-adhd-101 clinical study.
case-control study to identify risk factors for microscopic colitis

Conditions: Microscopic Colitis; Collagenous Colitis; Lymphocytic Colitis

Summary: the purpose of the study is to assess among others environmental and hygiene-related risk factors for microscopic colitis (mc), a common diarrheal disease.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of mc (cc or lc) between january 1, 2000 and december 31, 2012. * inhabitant of the province of limburg or the eindhoven region at the moment of diagnosis exclusion criteria: * below 18 years of age at the time of diagnosis * not capable of signing an informed consent * deceased at moment of approximation
the role of ophthalmologic tests and eeg imaging in alzheimer's disease

Conditions: Mild Cognitive Impairment

Summary: alzheimer's disease (ad) is a prevalent, long-term progressive degenerative disorder with great social impact. it is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the pathophysiology of the disease. meantime, eeg resting state has also demonstrated significant change in patients with ad in neuroscience research area. thus, the combination of these sensitive biomarkers would lead to a potential new biomarker for detection of ad, which has higher specificity and sensitivity.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease exclusion criteria: * neurologic disorders * psychiatric disorders

Keywords: ad eeg oct biomarker
a pharmacodynamic/pharmacokinetic study of aleglitazar in patients with type 2 diabetes mellitus on treatment with lisinopril

Conditions: Diabetes Mellitus Type 2

Summary: this randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effect of aleglitazar on renal function, the renin-angiotensin system and the pharmacokinetics of lisinopril in patients with type 2 diabetes mellitus treated with lisinopril. patients on a stable dose of lisinopril (20 mg daily orally) for 2 weeks will be randomized to receive either aleglitazar (150 mcg orally daily) or placebo in addition to lisinopril for 4 weeks.


Eligibility criteria:
inclusion criteria: * adult male and female patients, 18 to 65 years of age, inclusive * diabetes mellitus type 2, diagnosed at least 3 months before screening * treated with stable dose of metformin for at least 4 weeks prior to screening * treated with stable dose of angiotensin-converting enzyme inhibitor (acei) for at least 4 weeks prior to screening * body mass index (bmi) 18 to 38 kg/m2, inclusive exclusion criteria: * positive for hiv-1, hiv-2, hepatitis b or hepatitis c infection * pregnant or lactating females * type 1 diabetes or secondary from of diabetes * history or evidence of proliferative diabetic retinopathy or clinically significant neuropathy * clinically significant hepatic disease * clinically significant renal impairment * history or evidence of clinically significant cardio-vascular disease or disorder * acute infection or current malignancy requiring treatment except for excised basal cell carcinoma
quercetin as possible supportive therapy for mild to moderate hyperuricemia

Conditions: Hyperuricemia

Summary: uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. research has shown that supplementation with quercetin can significantly reduce plasma uric acid levels in individuals with mild hyperuricemia, potentially mitigating these associated risks.

uric acid, a metabolic byproduct of purine degradation in humans, is a significant risk factor for the development of gout and type 2 diabetes. supplementation with quercetin, a flavonol not naturally produced by the human body, has been shown to significantly reduce plasma uric acid levels in individuals with mild hyperuricemia. this effect is primarily achieved through the inhibition of xanthine oxidoreductase, an enzyme crucial to uric acid production. quercetin is the most abundant polyphenol found in fruits and vegetables and is widely used as a dietary supplement to boost the immune system and promote overall health. it is characterized by three key properties: antioxidant, anti-inflammatory, and immunomodulatory. these combined actions make quercetin a promising candidate for supporting various health conditions where oxidative stress, inflammation, and immune function play a role, including cardiovascular health, healthy aging, bone and joint health, sports and physical activity, gut health, and respiratory well-being. the above-described properties of quercetin prompted investigators to explore its potential uricosuric therapeutic effect in two clinical studies. the first study will assess this effect in a retrospective cohort of covid-19 patients who received quercetin as a supplemental therapy. in the second study, its potential uricosuric therapeutic effect will be assessed in a randomized controlled prospective clinical trial involving patients with mild to moderate hyperuricemia.

Eligibility criteria:
inclusion criteria: * aged between 18 and 75 years. * diagnosed with obesity. * diagnosed with hypercholesterolemia. * with or without moderate hyperuricemia (serum uric acid ≥ 8 mg/dl). * no restrictions on bmi, alcohol consumption, or smoking habits. exclusion criteria: * current use of uric acid-lowering medications (e.g., allopurinol, febuxostat). * diagnosed with oncological diseases. * diagnosed with neurological diseases. * diagnosed with inflammatory bowel diseases.
efficacy of vakum technology in patients with chronic hypersecretion

Conditions: Chronic Bronchitis/Bronchiectasis; Chronic Obstructive Pulmonary Disease

Summary: mechanical devices to increase the individual's bronchial hygiene are commonly used to assist patients with chronic retention of secretions. vaküm technology has been recently developed with the aim to improve the respiratory condition in hypersecretive patients suffering from chronic respiratory diseases. the aim of this study is to assess the clinical efficacy of vaküm technology in patients with hypersecretion, and chronic respiratory diseases a clinical trial has been designed. patients with chronic respiratory diseases, hypersecretion (sputum production \>30 ml/die), and reduced cough efficiency (peak cough expiratory flow \> 150 and \< 300 l\*min-1) referred to standard pulmonary rehabilitation (pr) will be included. study design is a single-blind multicentre randomized trial with consecutive recruitment. following a preliminary run-in period, group comparison will be made between intervention group using vaküm system (free aspire, mpr, legnano-i) added to the conventional manual eltgol technique, and control group using manual eltgol alone over 10 daily sessions. spirometric lung volumes, respiratory muscle strength, arterial blood gases, and quality of life will be recorded in both groups pre-to-post pr. perceived dyspnea (by vas scale), sputum volume and characteristics (on a semi-quantitative 3-point scale) and peak expiratory air flows (pef and pcef) will be registered on a daily basis over the study period. primary outcome is the change in perceived dyspnea; in order to ensure 80% power to detect a 5 point (sd 5) group difference change in the primary outcome at the end of the study period as significant at the 0.05 level, at least 42 patients per group are needed. the minimum target sample size will be then fixed at 50 patients per group. an higher and faster significant reduction of the perceived dyspnea is supposed in the intervention group. additional benefits among the secondary outcomes are also hypothesised in the same group.


Eligibility criteria:
inclusion criteria: * patients with chronic respiratory diseases * hypersecretion condition(sputum production \>30 ml/die) * reduced cough efficiency (peak cough expiratory flow \> 150 and \< 300 l\*min- 1) * patients admitted to standard pulmonary rehabilitation exclusion criteria: * not able to use the device * concomitant cardiovascular or neoplastic diseases * utilization of non invasive ventilation

Keywords: chest physiotherapy rehabilitation chronic respiratory diseases
study of markers of iron metabolism and their relationship with phosphocalcic and hepatic metabolism and inflammation in hemodialysis patients

Conditions: Iron Metabolism Disorders; Calcium Phosphate Metabolism; Hepatic Metabolic Disorders; Hemodialysis Complication

Summary: from a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure. the study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients. the main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. these two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.


Eligibility criteria:
inclusion criteria: * adult dialysis patient * patient able to understand the information necessary for the study and having signed his written consent to participate * affiliated patient or beneficiary of a social security scheme. exclusion criteria: * medically unstable or frail patient * patient with hemoglobin less than 7g/dl * patient with hiv+ or aids, patient with replicating hepatitis b or c * patient participating in another clinical study requiring an additional blood sample * patient benefiting from legal protection measures (guardianship, guardianship, etc.) adult under guardianship, guardianship or other legal protection, deprived of freedom by judicial or administrative decision * pregnant, breastfeeding or parturient woman
biomarkers in predicting neurotoxicity in patients with colorectal cancer receiving oxaliplatin

Conditions: Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neurotoxicity

Summary: rationale: studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in dna and identify biomarkers related to neurotoxicity. purpose: this phase ii trial is studying biomarkers in predicting neurotoxicity in patients with colorectal cancer receiving oxaliplatin.

objectives: primary * correlate predictive genetic, proteomic, and/or neurotrophic markers with neurological manifestations related to the administration of oxaliplatin in patients with colorectal carcinoma. secondary * differentiate between risk factors predictive of acute and chronic neurotoxicity. * establish a possible relationship between acute and chronic neurotoxicity. outline: this is a multicenter study. patients receive oxaliplatin every 2 weeks as part of a folfox chemotherapy regimen. blood samples are collected 15 days prior to beginning chemotherapy, prior to each course of chemotherapy, and at 1 month after completion of chemotherapy for pharmacogenetic and laboratory biological studies. patients with chronic neurotoxicity undergo additional blood sample collection at 3, 6, 9, and 12 months after completion of chemotherapy. samples are analyzed for the detection of gene variants involved in the oxalate and fluorouracil metabolic pathway; neurotrophic factors; proteomic analysis of plasma proteins and peptides; and for biological testing of neurotoxicity.

Eligibility criteria:
disease characteristics: * histologically confirmed colorectal cancer * requires treatment with oxaliplatin (as part of a folfox regimen) * no brain metastases or symptomatic meningitis patient characteristics: * who performance status 0-2 * life expectancy \> 3 months * anc ≥ 1 x 10\^9/l * platelet count ≥ 100 x 10\^9/l * total bilirubin ≤ 2 times upper limit of normal (uln) * transaminases ≤ 3 times uln * alkaline phosphatase ≤ 5 times uln * not pregnant or nursing * fertile patients must use effective contraception * no prior or concurrent clinical neuropathy (regardless of the etiology) * no dihydropyrimidine dehydrogenase deficiency * no psychiatric illness that would preclude comprehension of the study or of the informed consent * no other severe illness that may worsen during treatment, including unstable cardiac disease, myocardial infarction within the past 6 months, or active uncontrolled infection * no psychological, social, familial, or geographical reason that would preclude study follow-up * other cancer within the past 5 years allowed provided treatment did not include platinum derivatives or taxanes prior concurrent therapy: * see disease characteristics * prior chemotherapy allowed (except for platinum derivatives or taxanes)

Keywords: neurotoxicity chemotherapeutic agent toxicity recurrent colon cancer stage i colon cancer stage ii colon cancer stage iii colon cancer stage iv colon cancer recurrent rectal cancer stage i rectal cancer stage ii rectal cancer stage iii rectal cancer stage iv rectal cancer
combination of cpt-11 and lohp vs combination of 5-fu, leucovorin and lohp as 1st line treatment in gastric patients

Conditions: Gastric Cancer

Summary: this phase ii trial will compare the efficacy and toxicity of the combination of irinotecan and oxaliplatin versus 5-fu/lv and oxaliplatin as first line treatment in patients with locally advanced or metastatic gastric cancer

there is no regimen considered standard in advanced gastric cancer. the reported response rates of 5-fu-based combination chemotherapy are higher than single agents (10-50%) but more toxic. the combination of 5-fu/lv and lohp has demonstrated an orr of 43%, median ttp of approximately 6,5 months and os of 8,6 months in phase ii trials, with an acceptable toxicity. irinotecan (cpt-11) is effective as salvage treatment in metastatic gastric cancer and has a synergistic activity with lohp in preclinical trials

Eligibility criteria:
inclusion criteria: * histologically confirmed locally advanced or metastatic gastric cancer. * measurable or evaluable disease. * measurable disease is defined as at least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or 1 bidimensionally measurable lesion ≥ 20 x 10 mm. lesions that are smaller or uni- or bidimensionally unmeasurable are considered as evaluable disease. * previous adjuvant chemotherapy with irinotecan, oxaliplatin and/or 5-fu based regimen. patients who relapse within the first 6 months after the completion of adjuvant treatment are not eligible for the study. * karnofsky performance status \> 70%. * age ≥18 years. * adequate liver (bilirubin ≤ 1.5 unl, sgot/sgpt ≤ 4 unl, alp ≤ 2.5 unl), renal (creatinine ≤ 1.5 unl) and bone marrow (anc ≥ 1,500/mm3, plt ≥ 100,000/mm3) function. * patients must be able to understand the nature of this study and give written informed consent. exclusion criteria: * active infection * history of serious cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * previous radiotherapy within the last 4 weeks or \> 25% of bone marrow. * patients with cns metastases * patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction. * malnutrition or loss of \> 10% of body weight during the last month. * peripheral neuropathy ≥ grade 2 * second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer. * psychiatric illness or social situation that would preclude study compliance. * pregnant or lactating women.

Keywords: metastatic gastric cancer oxaliplatin irinotecan
long term safety protocol for the acrysof cachet phakic lens

Conditions: Myopia

Summary: the purpose of this long term safety study is to estimate the annualized endothelial cell loss (ecl) rate (for up to 10 years following date of implantation) of subjects previously implanted with the acrysof cachet phakic intraocular lens (l-series) from precursor clinical studies c-02-23, c-02-40, c-03-21 and c-05-57.

subjects previously enrolled in protocols c-02-23 (nct00726024), c-02-40 (nct00727805), c-03-21 (nct00726297), and c-05-57 (nct00727688) who received an l-series lens either in the first eye or second eye (including those who were explanted) were enrolled in this open-label, non-randomized, non-controlled, extension study in which they attended postoperative visits for up to 10 years following the date of implantation. subjects could enroll in the study at any time, thus the entrance visit may have coincided with any visit (year 4 to year 10).

Eligibility criteria:
inclusion criteria: * previously implanted with an acrysof cachet phakic lens (l-series) from clinical studies c-02-23, c-02-40, c-03-21 and c-05-57 and eligible for continued follow-up (i.e., exited from the previous study). * able to understand and sign a statement of informed consent. * willing and able to complete the yearly postoperative study visits. exclusion criteria: * none

Keywords: phakic lens intraocular lens (iol)
project tap: tailored activities project

Conditions: Alzheimer's Disease

Summary: specific aims 1. establish a preliminary effect size for the impact of the intervention on depressive affect and agitated behaviors in persons with dementia in 4 months 2. evaluate acceptance of and engagement in activities in persons with dementia 3. establish a preliminary effect size for the impact of the intervention on caregiver burden, depressive symptoms, and mastery at 4 months. 4. evaluate caregiver skills acquisition, acceptance of and compliance to intervention techniques.


Eligibility criteria:
inclusion criteria: * care recipient * english speaking * nincds-adrda diagnosis\[physician generated of dementia or mini-mental state examination score of less than or equal to 23;3\] able to feel self; and participates in at least 2 other activities of daily living\[adls-bathing, dressing, grooming, toileting, transferring from bed to chair\] as reported by caregiver. * caregiver * english speaking * family member 21 years of age or older \[male or female\] * lives with care recipient * has telephone in the home * plans to live in area for 8 months * indicated willingness to learn new approaches by which to engage care recipient in meaningful activities * provides 4 or more hours a day directly caring or providing for care recipient exclusion criteria: * care recipient * has schizophrenia or bi-polar disorder * their dementia is secondary to probable head trauma * their mmse score is equal to zero and they are bed bound, defined as confinement to bed or chair for at least 22 hours a day for at least 4 of 7 days * they are not responsive to their environment * caregiver * are currently involved in another clinical trial of psycho-social or educational interventions for caregivers * are planning to place their family member in a nursing home within the next 8 months. also, the care recipient/caregiver dyad will be excluded if either caregiver or care recipient: 1) has a terminal illness with life expectancy less than 8 months 2)is in active treatment for cancer or 3) has had greater than 3 acute medical hospitalizations within the past year.

Keywords: activity, dementia, caregiving
the effect of external pressure applı̇ed to the palm on labor paı̇n and childbirth experı̇ence

Conditions: Labor Pain

Summary: the study was carried out to evaluate the effect of external pressure applied to the palm on labor pain and childbirth experience.the sample of the randomized controlled study consisted of 60 nulliparous (30 in the experimental group and 30 in the control group) pregnant women who presented to zeynep kamil gynecology and pediatrics training and research hospital between april and june 2020 to give birth and met the research conditions. the descriptive information form, follow-up form related to labor action, childbirth experience questionnaire (ceq), and visual analogue scale (vas) were used in data collection. during the 5-6 cm, 7-8 cm, and 9-10 cm cervical dilatation stages of the labor process, palm external pressure was applied to the pregnant women in the experimental group, while standard midwifery care was provided to the pregnant women in the control group. the vas was applied to both groups at admission to the hospital, before and after the 5-6 cm, 7-8 cm, and 9-10 cm cervical dilatation stages, and also at the 30th minute postpartum. data were analyzed statistical package for social sciences 24.0 program using number, percentage, mean, standard deviation, the kolmogorov-smirnov test, levene's test and independent samples t-test, one-way anova test, analysis of variance, and chi-square test. in all analyses, p\<0.05 values will be considered statistically significant.

labor pain adversely affects pregnant women's perception of the labor process and childbirth. when not taken under control, it causes pregnant women to have negative experiences about the labor process and consequently leads to a decrease in their satisfaction with childbirth. for this reason the study was carried out to evaluate the effect of external pressure applied to the palm on labor pain and childbirth experience. hypotheses of the research; h 1 : external pressure applied to the palm during labor reduces the level of labor pain. h 1 : external pressure applied to the palm during labor increases the positive birth experience.

Eligibility criteria:
inclusion criteria: * being aged between 18-35 years * being a nulliparous pregnant woman * being pregnant at term (between the 37th and 42nd weeks of gestation) * expecting the vaginal delivery * being in singleton and vertex presentation * the weight of the fetus between 2500-4000 g * having had an uncomplicated pregnancy process for the pregnant woman and the fetus * being in the latent phase (cervical dilatation below 4 cm) exclusion criteria: * having high-risk pregnancy * having any disease and disability related to the hand and palm * having any health problem preventing communication * being a pregnant woman in need of analgesics * pregnant women to whom non-pharmacological methods were applied to relieve pain * undergoing cesarean section due to possible indication

Keywords: external pressure labor pain childbirth experience non-pharmacological method midwifery care